Sabre announces upcoming webcast of third quarter 2023 earnings conference call
Get Alerts SABR Hot Sheet
Join SI Premium – FREE
About Sabre
Sabre Corporation is a leading software and technology company that powers the global travel industry, serving a wide range of travel companies including airlines, hoteliers, travel agencies and other suppliers. The company provides retailing, distribution and fulfilment solutions that help its customers operate more efficiently, drive revenue and offer personalized traveler experiences. Through its leading travel marketplace, Sabre connects travel suppliers with buyers from around the globe. Sabre's technology platform manages more than $260B worth of global travel spend annually. Headquartered in Southlake,
Website Information
We routinely post important information for investors on the Investor Relations section of our website, investors.sabre.com, and on our Twitter account, @Sabre_Corp. We intend to use the Investor Relations section of our website and our Twitter account as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website and our Twitter account, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website or our Twitter account is not incorporated by reference into, and is not a part of, this document.
SABR-F
Contacts
Media
[email protected]
[email protected]
Investors
[email protected]
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/sabre-announces-upcoming-webcast-of-third-quarter-2023-earnings-conference-call-301963232.html
SOURCE Sabre Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CuriosityStream names Sean Piche as CFO, effective September 1
- Hanover Bancorp approves repurchase of up to 370,000 shares
- FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share